Role of antiplatelet therapy in cardiovascular disease I: Acute coronary syndromes.
The acute coronary syndromes (ACS), consisting of ST-segment elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), and unstable angina, remain a leading cause of death in the United States. Through the process of atherothrombosis, underlying atherosclerosis can progress to an acute ischemic coronary event. This disease mechanism is also common to ischemic stroke and peripheral arterial disease. As ACS is a heterogeneous disease, accurate patient diagnosis and risk categorization is essential. Treatment approaches for both STEMI and NSTEMI ACS consist of a combination of surgical intervention and pharmacotherapy, with antiplatelet agents such as clopidogrel, aspirin and glycoprotein IIb/IIIa receptor antagonists playing an essential role.
Cavendish
Jeffrey J
JJ
Department of Cardiology, Naval Medical Center, San Diego, CA 92134, USA. JJCavendish@nmcsd.med.navy.mil
Fugit
Randolph V
RV
Safani
Michael
M
D000328:Adult; D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013577:Syndrome; D014029:Tobacco Use Disorder / Q000150:complications
D010975:Platelet Aggregation Inhibitors